Ottignies-Louvain-La-Neuve

• Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II … Not authorised
  2023-503480-42-00 10 Hospital-acquired pneumonia
• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br … Pending
  2024-518026-32-00 5 Invasive Breast Cancer
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o … Pending
  2025-521632-12-00 5 Patients on Factor Xa inhibitor treatment needing an urgent interventi
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy Recruiting
  2024-515635-30-00 3 2026-03-24 Coagulopathy
• A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting
  2024-513911-28-00 10 2026-03-04 Acute Ischemic Stroke
• Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international … Recruiting
  2023-508153-12-00 5 2024-03-26 Hospital-acquired pneumonia
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• A trial to learn how well AZD4144 works, how safe it is, and how it moves throughout the body over time in adults with acute kidney injury c … Recruiting
  2025-522232-13-00 4 2026-03-06 Sepsis-associated acute kidney injury (AKI)
• Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-520927-26-00 5 2025-11-24 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• A pHase III cluster randomIsed controlled, cross-over, non-inferiority Trial of a short course, High dose AntimicRobials vs conventional dos … Recruiting
  2024-514730-21-00 5 2025-07-01 Bacterial infections and mycoses
• Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation-2 (TELSTAR-2): a multicenter randomised clinical … Recruiting
  2024-516068-27-01 5 2025-04-10 cardiopulmonary resuscitation
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Hypertonic lactate after cardiac arrest Recruiting
  2023-506031-15-01 4 2025-02-18 post-anoxic brain injury
• A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-514281-39-00 5 2025-02-14 Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-515008-38-00 5 2025-02-14 Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
• A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR … Recruiting
  2023-510109-16-00 4 2025-01-06 Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma

Showing 1–24 of 49 trials